Biohaven (BHVN)

Executive Summary

Biohaven is a clinical-stage biopharmaceutical company rebuilding its pipeline after divesting its migraine franchise to Pfizer in 2022. The company leverages proprietary platforms in glutamate modulation, myostatin inhibition, and Kv7 ion channel targeting to develop therapies for neurological, neuropsychiatric, immunological, and oncological diseases. Its diversified portfolio includes late-stage programs such as troriluzole for obsessive-compulsive disorder (Phase 3 completed) and BHV-7000, a Kv7 activator, for focal and generalized epilepsy (Phase 2/3). BHV-7000 is also being evaluated in major depressive disorder (Phase 2) and represents a key pipeline asset with potential for broad CNS indications. Near-term catalysts center on BHV-7000 data readouts. The focal epilepsy trial (NCT06309966) is expected to complete in May 2026, with top-line results likely in the second half of 2026. If positive, BHV-7000 could advance to registration, positioning Biohaven for a potential NDA filing. Additional catalysts include regulatory updates for troriluzole in OCD, which completed its Phase 3 trial in April 2025, and early-stage proof-of-concept data for other pipeline candidates. Biohaven's strong cash position and multiple shots on goal support a favorable risk/reward profile.

Upcoming Catalysts (preview)

• H2 2026BHV-7000 Phase 2/3 Focal Epilepsy Top-Line Results65% success
• H2 2026Troriluzole Regulatory Update for OCD (Phase 3 Completed)50% success
• H1 2027BHV-7000 Phase 2/3 Generalized Epilepsy Interim Data55% success